Search the Newsreel

AbbVie (ABBV) Stock May Trade At A Premium Despite Cash Flow Upside

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value …

Park National Corp OH Lowers Stake in Abbott Laboratories $ABT

Park National Corp OH reduced its stake in Abbott Laboratories by 10.2% in the second quarter, selling 17,000 shares but still retaining 150,182 shares valued at approximately $13.6 million. Despite this reduction and some analysts lowering price targets, the consensus rating for Abbott remains …

QRG Capital Management Inc. Lowers Holdings in Abbott Laboratories $ABT

QRG Capital Management Inc. reduced its stake in Abbott Laboratories (NYSE:ABT) by 28.7% in the second quarter, selling 83,416 shares and retaining 207,173 shares worth approximately $18.8 million. Despite this reduction, institutional investors collectively own 75.18% of ABT. Abbott Laboratories recently reported stronger-than-expected quarterly …

AbbVie (ABBV) Stock May Be 45% Undervalued On Raised 2026 Outlook

Abbott Laboratories Revenue Breakdown – AQUISUK:ABLD

This article provides a revenue breakdown for Abbott Laboratories (ABLD) on the Aquis Stock Exchange. It highlights that in the last year, the company generated 37.74 billion EUR, with Medical Devices being the top-performing segment at 18.21 billion EUR. The United States was the …

Can Abbott Laboratories (ABT)’s Lingo Partnership With Alphabet (GOOG) Unlock a New Era of AI-Powered Health?

On August 11, medtech leader Abbott Laboratories (NYSE:ABT) and tech behemoth Alphabet Inc. (NASDAQ:GOOG) announced a multi-year partnership to unite continuous glucose monitoring with consumer AI. The collaboration embeds data from Abbott's non-prescription Lingo biowearable directly into the Google Health app, combining real-time metabolic …

2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical AbbVie has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained …

Die AbbVie-Aktie legt nach starkem Q2-2026-Bericht und angehobener Prognose zu

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu

Abbott Laboratories: Revenue and Earnings Analysts Forecasts Revisions | ABT | US0028241000

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

Abbott India Shares Fall Over 2%

Top Abbott Executive Makes Bold Move With Fresh Insider Stock Sale

An executive at Abbott Laboratories (ABT), Louis H. Morrone, recently sold 5,850 shares of company stock for $642,505. This insider transaction provides investors with additional data to consider regarding the company's current valuation. Abbott's stock performance and analyst ratings are influenced by its strong …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

The Sharpest Exchanges From ABBV’s Earnings Call

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Abbott Laboratories (NYSE:ABT) Raised to Outperform at Wolfe Research

Wolfe Research upgraded Abbott Laboratories (NYSE:ABT) to "outperform" from "peer perform," setting a $130 price target, which suggests a 17.2% upside. This upgrade comes after Abbott's recent quarterly results surpassed expectations, with EPS of $1.31 and revenue of $12.59 billion, an increase of 13% …

What's Backing Abbott's Established Pharmaceuticals Division Growth

Abbott Laboratories' ABT Established Pharmaceuticals Division ("EPD") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis …

Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle

Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter …

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

This article details Wall Street analyst upgrades, downgrades, and initiations for various companies on Thursday, August 13, 2026, following the release of inline CPI data. Key movements include Five Below being upgraded to Buy at Jefferies and StubHub being cut to Underperform at Bank …

Die Abbott-Laboratories-Aktie legt nach starken Quartalszahlen und solider Guidance zu

Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300

Wolfe has upgraded AbbVie (ABBV) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a more positive outlook on the pharmaceutical company's stock performance. The article also lists recent news and analyst actions related to AbbVie, …

AbbVie Inc. $ABBV Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, now holding 69,052 shares valued at $17.4 million. This move is part of a broader trend of institutional investors and hedge funds holding 70.23% of AbbVie's …

V. M. Manning & CO. Inc. Acquires New Position in Abbott Laboratories $ABT

V. M. Manning & CO. Inc. has acquired a new stake in Abbott Laboratories, purchasing 19,849 shares valued at approximately $1.8 million, making it their 11th largest holding. This move comes as Abbott Laboratories exceeded its quarterly earnings expectations and maintains a positive outlook …

McCollum Christoferson Group LLC Sells 62,644 Shares of Abbott Laboratories $ABT

Abbott India Q1 FY27 Results: Revenue Rs 1,813 Cr, PAT Rs 428 Cr and Key Highlights

Abbott India Shares Fall 2.03% to Rs 27,570; Among Top Losers on Nifty Midcap 150

Abbott Laboratories $ABT Shares Acquired by DAVENPORT & Co LLC

Abbott Laboratories Aktie | US0028241000 | ETR:ABL | News & Aktienkurs | FRA:ABL

Rep. Mike Kelly Unloads Abbott Laboratories (NYSE:ABT) Shares

Representative Mike Kelly sold shares of Abbott Laboratories (NYSE:ABT) valued between $1,001 and $15,000 on July 17th, as well as shares of PepsiCo and Walt Disney on the same day. This sale occurred despite Abbott Laboratories reporting a quarterly earnings beat and reaffirming its …

Mike Kelly makes multiple trades including Abbott Laboratories and Disney stocks

Congressman Mike Kelly recently executed several trades through the Victoria Kelly Trust ICA, including selling stocks from Abbott Laboratories and The Walt Disney Company, each valued between $1,001 and $15,000. He also sold Pepsico, Inc. stocks worth $15,001 to $50,000. Additionally, Kelly purchased government …